Roquefort Therapeutics plc
LSE ROQ.L
Roquefort Therapeutics plc Debt to Equity Ratio for the year ending December 31, 2023
Roquefort Therapeutics plc Debt to Equity Ratio is NA for the year ending December 31, 2023. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
Key data
| Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
|---|
Market news
Loading...
Don’t Miss A Beat
LSE: ROQ.L
| CEO | Mr. Trevor Ajanthan Reginald |
| IPO Date | March 22, 2021 |
| Location | United Kingdom |
| Headquarters | Eccleston Yards |
| Employees | 10 |
| Sector | Healthcare |
| Industries | |
Description
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Key trends
Past 5 years
StockViz Staff
February 7, 2025
Any question? Send us an email